Status: Recruiting
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Narrows Institute for Biomedical ResearchUpdated: May 6, 2025Locations: 1
Eligibility criteria
Men and women ages 18+. [+4]
Subject has any skin pathology or condition that could interfere with the evalua... [+8]